• Dasatinib (BMS-354825) in EMT and Kinase-Driven Cancer Resea

  2026-05-25

  Dasatinib (BMS-354825) stands apart as a powerful tool for dissecting kinase signaling, EMT, and stemness in cancer models. This article delivers actionable protocols, troubleshooting strategies, and translational insights rooted in recent multi-omics research.

• Olive Biophenols Mitigate Alzheimer’s Pathology in Cell and

  2026-05-25

  The reference study demonstrates that olive biophenols, especially oleuropein, verbascoside, and rutin, significantly reduce amyloid beta-induced toxicity in SH-SY5Y neuroblastoma cells and decrease amyloid plaque deposition in transgenic Alzheimer’s mice. These findings highlight the potential of natural plant compounds in modifying amyloid pathology and inform future translational research on neurodegenerative disease interventions.

• Bifendate Inhibits Autophagy and Reduces Lipid Accumulation

  2026-05-24

  This study elucidates how bifendate (DDB), a hepatoprotective agent, inhibits multiple steps of autophagy and attenuates oleic acid-induced lipid accumulation in vitro. The findings provide mechanistic insight into DDB's role in cellular lipid regulation, with implications for liver disease research.

• Discovery of Allosteric PDK4 Inhibitors for Metabolic Diseas

  2026-05-23

  The reference study identifies and characterizes novel allosteric inhibitors of pyruvate dehydrogenase kinase 4 (PDK4), with compound 8c demonstrating potent in vitro and in vivo efficacy in models of metabolic, allergic, and oncological diseases. These findings offer a new scaffold for targeted metabolic disease therapies and highlight the translational potential of PDK4 inhibition.

• SNS-032 (BMS-387032): CDK Inhibition for Cancer and Virology

  2026-05-22

  SNS-032 (BMS-387032) offers researchers a potent, selective tool to dissect cell cycle regulation and transcriptional control, with proven efficacy in cancer and host-targeted antiviral workflows. Its robust inhibition of CDK2/7/9 and downstream effects on RNA Pol II phosphorylation uniquely position it for both apoptosis induction and the study of viral egress mechanisms.

• Dasatinib (BMS-354825): Applied Workflows in Kinase Research

  2026-05-22

  Dasatinib (BMS-354825) delivers precision kinase inhibition for dissecting Src and Bcr-Abl signaling in cancer models. This guide highlights protocol optimization, advanced applications, and troubleshooting strategies that empower researchers to maximize data quality in both cellular and animal workflows.

• Quizartinib (AC220): Precision in FLT3 Inhibition for AML Re

  2026-05-21

  Quizartinib (AC220) redefines targeted kinase inhibition in acute myeloid leukemia research, enabling high-sensitivity interrogation of FLT3-driven signaling and drug resistance. This guide details robust workflows, advanced applications, and actionable troubleshooting for maximizing experimental reproducibility with this potent FLT3 inhibitor.

• Quizartinib (AC220): Optimizing FLT3 Inhibition in AML Resea

  2026-05-21

  Quizartinib (AC220) empowers acute myeloid leukemia (AML) research with unparalleled selectivity for FLT3, enabling robust, reproducible results in both in vitro and in vivo settings. This guide delivers actionable protocols, troubleshooting strategies, and translational insights—backed by the latest evidence on overcoming drug resistance in myeloid malignancies.

• Ceftolozane/Tazobactam: Advances in Combating Resistant Gram

  2026-05-20

  This review analyzes the therapeutic innovation of ceftolozane/tazobactam, a novel cephalosporin/β-lactamase inhibitor combination, highlighting its enhanced efficacy against resistant Gram-negative pathogens, including Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. The paper’s findings inform antibiotic selection and resistance management, and contextualize current research strategies utilizing mechanistically distinct agents like synthetic fluoroquinolone antibiotics.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 to Protect Against CI-A

  2026-05-20

  The reference study demonstrates that Chenodeoxycholic Acid (CDCA), via activation of the nuclear receptor FXR, upregulates KLF11 expression and suppresses the JAK2/STAT3 pathway in models of contrast-induced acute kidney injury (CI-AKI). These findings clarify a novel FXR-KLF11-mediated mechanism for renal protection and support the strategic use of FXR agonists in metabolic and kidney disease research.

• Dasatinib Monohydrate: Precision Workflows in CML and Ph+ AL

  2026-05-19

  Dasatinib Monohydrate (BMS-354825) is redefining kinase pathway interrogation in chronic myeloid leukemia and Philadelphia chromosome-positive models, delivering nanomolar potency even against imatinib-resistant BCR-ABL forms. This article translates advanced research findings into actionable workflows, troubleshooting tips, and protocol refinements for preclinical and translational scientists.

• Deferoxamine Mesylate: Iron-Chelating Agent for Oxidative St

  2026-05-19

  Deferoxamine mesylate is a potent iron-chelating agent that sequesters labile iron and mitigates iron-mediated oxidative damage. It is widely used in research on ferroptosis, hypoxia signaling, and tumor inhibition. Its mechanism and efficacy are supported by robust preclinical and molecular evidence.

• Lopinavir (ABT-378): Precision HIV Protease Inhibition in Re

  2026-05-18

  Lopinavir (ABT-378) delivers unmatched efficacy and resistance resilience in HIV protease inhibition assays, even in serum-rich conditions. This guide translates advanced bench research into actionable protocols and troubleshooting strategies, solidifying Lopinavir's role as the gold standard for next-generation antiviral research.

• Perospirone (SM-9018 Freebase): Mechanisms and Research Uses

  2026-05-18

  Perospirone (SM-9018 freebase) is an atypical antipsychotic with high affinity for 5-HT2A, D2, and 5-HT1A receptors, and a novel inhibitor of vascular Kv1.5 channels. Its dual action underpins its utility in schizophrenia research and cardiovascular models. Key numeric claims in this article are supported by peer-reviewed data and APExBIO product specifications.

• Nascent Cone Precursors Identified as Cell-of-Origin in Reti

  2026-05-17

  This study utilizes single-cell longitudinal analysis of RB1-deficient human retinal organoids to pinpoint ATOH7+ nascent cone precursors as the earliest cell-of-origin for human retinoblastoma. The findings clarify the temporal sequence and cellular mechanisms underlying tumor initiation, providing a crucial foundation for targeted therapeutic strategies.

14826 records 1/989 page Next 12345 下5页 Last page